CASI Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
CASI Pharmaceuticals | EFFECT: Others
CASI Pharmaceuticals | CORRESP: CORRESP
CASI Pharmaceuticals | F-3/A: Registration statement for specified transactions by certain foreign private issuers (Amendment)
CASI Pharmaceuticals | UPLOAD: Others
CASI Pharmaceuticals | F-3: Registration statement for specified transactions by certain foreign private issuers
CASI Pharmaceuticals | 6-K: Report of foreign private issuer (related to financial reporting)
CASI Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
CASI Pharmaceuticals | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-WEI-WU HE, Ph.D.(20.94%),EMERGING TECHNOLOGY PARTNERS, LLC(7.1%), etc.
CASI Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-Venrock Healthcare Capital Partners III, L.P.(9.99%),VHCP Co-Investment Holdings III, LLC(9.99%), etc.
CASI Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
CASI Pharmaceuticals | D: Filing D
CASI Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
CASI Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
CASI Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
CASI Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-Foresite Capital Fund VI, L.P. (“FCF VI”)(9.8%),Foresite Capital Management VI, LLC (“FCM VI”)(9.8%), etc.
CASI Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-James Huang(8.4%),Panacea Venture Healthcare Fund II, L.P.(7.6%), etc.
CASI Pharmaceuticals | UPLOAD: Others
CASI Pharmaceuticals | CORRESP: CORRESP
CASI Pharmaceuticals | UPLOAD: Others
No Data
No Data